Comparative Pharmacology
Head-to-head clinical analysis: MD 60 versus RENOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 60 versus RENOVIST.
MD-60 vs RENOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-60 is a nonionic iodinated contrast agent. It attenuates X-rays by increasing the density of structures and organs, improving radiographic visualization.
RENOVIST is a radiocontrast agent that enhances imaging by attenuating X-rays due to its iodine content. It acts by increasing the density of blood vessels and tissues, improving contrast in radiographic studies.
Intravenous administration, 60 mg/kg as a single dose over 30 min.
0.5-1 mg/kg intravenously daily
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function (CrCl >90 mL/min); prolonged to >40 hours in moderate renal impairment (CrCl 30–60 mL/min), requiring dose adjustment.
Terminal half-life: 12 hours; in renal impairment (CrCl <30 mL/min) prolonged to 24-36 hours; dose adjustment required
Primarily renal elimination of unchanged drug (~60% within 24 hours) via glomerular filtration; biliary/fecal excretion accounts for ~30% as metabolites; ~10% undergoes enterohepatic recirculation.
Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent